We are live on ! Find out more
GTC

Ghost Tree Capital Portfolio holdings

AUM $331M
1-Year Est. Return 70.11%
This Fund
S&P 500
This Quarter Est. Return
+26.31%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$471M
AUM Growth
-$10.2M
Cap. Flow
-$72.7M
Cap. Flow %
-15.44%
Top 10 Hldgs %
41.74%
Holding
94
New
28
Increased
11
Reduced
21
Closed
31

Top Buys

1
TMO icon
Thermo Fisher Scientific
TMO
+$9.06M
2
XLRN
Acceleron Pharma
XLRN
+$9.03M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.53M
4
IMMU
Immunomedics Inc
IMMU
+$7.44M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$7.03M

Top Sells

1
SGEN
Seagen Inc. Common Stock
SGEN
+$15.5M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$11.2M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$8.95M
4
ENDP
Endo International plc
ENDP
+$8.38M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$8.03M

Sector Composition

1 Healthcare 57.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONCE
26
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$7.13M 1.51%
80,000
+45,000
+129% +$3.42M
IRTC icon
27
iRhythm Holdings
IRTC
$3.64B
$7M 1.49%
135,000
-15,000
-10% -$679K
RXDX
28
DELISTED
Ignyta, Inc.
RXDX
$6.79M 1.44%
+550,000
New +$5.67M
PDCO
29
DELISTED
Patterson Companies, Inc.
PDCO
$6.18M 1.31%
+160,000
New +$6.39M
ICPT
30
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$5.8M 1.23%
+100,000
New +$10.8M
ARGX icon
31
argenx
ARGX
$53.8B
$5.71M 1.21%
252,534
+56,247
+29% +$1.17M
NGNE icon
32
Neurogene
NGNE
$744M
$5.68M 1.21%
20,000
+5,000
+33% +$1.44M
NSTG
33
DELISTED
NanoString Technologies, Inc.
NSTG
$5.58M 1.19%
345,284
-4,716
-1% -$72.8K
GWPH
34
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$5.08M 1.08%
50,000
-75,000
-60% -$8.03M
AIMT
35
DELISTED
Aimmune Therapeutics
AIMT
$4.96M 1.05%
200,000
-50,000
-20% -$1.08M
BMY icon
36
Bristol-Myers Squibb
BMY
$124B
$4.78M 1.02%
+75,000
New +$4.38M
SRPT icon
37
Sarepta Therapeutics
SRPT
$1.82B
$4.54M 0.96%
+100,000
New +$4M
JUNO
38
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.49M 0.95%
100,000
-175,000
-64% -$5.97M
MRK icon
39
Merck
MRK
$315B
$4.16M 0.88%
+68,120
New +$4.13M
ALNY icon
40
Alnylam Pharmaceuticals
ALNY
$35.7B
$4.11M 0.87%
+35,000
New +$2.99M
ACAD icon
41
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
$4.11M 0.87%
+109,000
New +$3.55M
INCY icon
42
Incyte
INCY
$23.4B
$4.09M 0.87%
+35,000
New +$4.43M
VRAY
43
DELISTED
ViewRay, Inc.
VRAY
$4.03M 0.86%
700,000
-50,000
-7% -$282K
FXB icon
44
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
$3.92M 0.83%
30,100
-20,800
-41% -$2.65M
AIMT
45
CALL
DELISTED
Aimmune Therapeutics
AIMT
$3.72M 0.79%
+150,000
New +$3.23M
NEOS
46
DELISTED
Neos Therapeutics, Inc
NEOS
$3.66M 0.78%
400,000
-100,000
-20% -$760K
AERI
47
DELISTED
Aerie Pharmaceuticals
AERI
$3.65M 0.77%
+75,000
New +$4.09M
RARX
48
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.43M 0.73%
235,000
+150,000
+176% +$2.27M
FOLD
49
DELISTED
Amicus Therapeutics
FOLD
$3.02M 0.64%
+200,000
New +$2.65M
KDMN
50
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.85M 0.6%
+850,000
New +$2.43M
1
2
3 4

Similar funds

SF
Susquehanna Foundation Bala Cynwyd, Pennsylvania $333M AUM 35.73% 1-Year Est. Return
AFS
Annapolis Financial Services Annapolis, Maryland $338M AUM 23.49% 1-Year Est. Return
SFA
Source Financial Advisors New York $338M AUM 33.62% 1-Year Est. Return
E
ETFidea Syracuse, New York $316M AUM 29.57% 1-Year Est. Return
OHCM
Oak Hill Capital Management New York $310M AUM 17.23% 1-Year Est. Return
MC
Minot Capital Broomfield, Colorado $353M AUM 25.25% 1-Year Est. Return
BRA
Biechele Royce Advisors Fishers, Indiana $303M AUM 20.64% 1-Year Est. Return
S
Syntrinsic Denver, Colorado $301M AUM 27.27% 1-Year Est. Return

Ghost Tree Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Ghost Tree Capital held 94 positions worth $471M, down 2.1% from $481M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ghost Tree Capital withdrew a net $72.7M in Q3 2017, closing 31 positions and reducing 21 holdings. Its most notable exit was Seagen Inc. Common Stock, an estimated $15.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 58% of assets, down from 59% a quarter earlier.

Against the trend, Ghost Tree Capital opened a new position in Thermo Fisher Scientific worth $9.46M.

  • Ghost Tree Capital's largest Q3 2017 buy was Thermo Fisher Scientific: 50,000 shares worth $9.46M.
  • Ghost Tree Capital added most to Acceleron Pharma in Q3 2017, an estimated $9.03M increase.
  • Ghost Tree Capital's biggest Q3 2017 reduction was GW Pharmaceuticals Plc American Depositary Shares, cutting an estimated $8.03M.
  • Ghost Tree Capital fully exited Seagen Inc. Common Stock in Q3 2017, selling an estimated $15.5M.
  • Ghost Tree Capital's ten largest holdings make up 42% of its $471M portfolio in Q3 2017.
  • Ghost Tree Capital opened 28 new positions and closed 31 in Q3 2017.
  • Ghost Tree Capital's portfolio value fell 2.1% quarter-over-quarter to $471M.

Based on Ghost Tree Capital's 13F filing for Q3 2017, filed 14 Nov 2017.